To further investigate the significance of our experimental findings for demyelinating diseases, we performed different combinations of CXCR4, AR, MBP, GFAP and MPZ immunolabeling on autopsied spinal cord sections from 5 men and 5 women with secondary progressive (SP) or primary progressive (PP) multiple sclerosis (MS). This evidence concerns the gene GFAP and myeloid sarcoma.